FibroGen (NASDAQ:FGEN) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPS

FibroGen (NASDAQ:FGEN) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09, Zacks reports. The company had revenue of $50.64 million during the quarter, compared to analysts’ expectations of $33.00 million. During the same quarter in the prior year, the company earned ($0.65) EPS.

FibroGen Stock Performance

Shares of NASDAQ FGEN traded down $0.02 during midday trading on Thursday, reaching $0.44. 2,089,256 shares of the company’s stock were exchanged, compared to its average volume of 2,676,570. FibroGen has a 52-week low of $0.33 and a 52-week high of $2.93. The business’s fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.43. The stock has a market capitalization of $43.85 million, a PE ratio of -0.18 and a beta of 0.71.

Insider Activity at FibroGen

In other FibroGen news, insider Deyaa Adib acquired 22,123 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were bought at an average cost of $1.17 per share, for a total transaction of $25,883.91. Following the acquisition, the insider now directly owns 82,123 shares of the company’s stock, valued at $96,083.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Monday, June 3rd.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.